After listening to Andrew Witty explain the new, high volume strategy in the interview on CNBC, it seems to me he is basically saying that GSK plans to out-compete generic manufacturers on off-patent medicines. Is this really the most profitable way to use the talents of the company?
I am pretty sure that now all the real talent has left GSK the remaining gender and diversity ass clowns that are left probably couldn't even sell a $4 generic.
AW is either a liar or a bit dim. five years ago he was boasting about his pipeline and how LLY or AZN would need to be acquired to survive three years ago he was boasting about others falling over the patent cliff while GSK had already emerged on the brighter side two years ago he was boasting about pharma launches in respiratory, oncology and vaccines last year he was boasting about growth excluding supply chain issues Always boasting about GSK's superior values and new selling strategy results We've lost credibility in Pharma and would be happy to be acquired by LLY/AZN/PFE We're now realizing the patent cliff is ahead not behind us Our pipeline has been a huge and expensive dud while our acquisitions have failed Supply chain issues were caused by AW's lack of understanding and fear. This has continued in 2015 and will defeat the "volume growth" strategy AW has touted. GSK doesn't play by the rules and has been outed in China and will be outed in a host of other markets (just the beginning).
Please everybody read todays Forbes online. It talks about Sir Andrew leading GSK. Not a great vote of confidence.